Integer Holdings Corp current report, Q2 FY2018

Abrir documento

Business Context and Reporting Period

Company: Integer Holdings Corporation
Filing Type: Form 8-K (Current Report)
Date of Report: June 8, 2018
Context: The Company entered into Amendment No. 4 to its Credit Agreement and issued notice of a conditional full redemption of its outstanding Senior Notes. These actions are directly tied to the previously announced sale of the Company's Advanced Surgical and Orthopedic ("AS&O") product lines.

Key Financial Metrics and Obligations

  • Debt Instrument: 9.125% Senior Notes due 2023.
  • Outstanding Principal: $360.0 million (as of June 8, 2018).
  • Redemption Price: 100% of principal plus applicable premium and accrued interest.
  • Planned Use of Proceeds (AS&O Sale):
    1. Redeem all outstanding 9.125% Senior Notes.
    2. Repay outstanding revolving credit loans (without reducing the credit commitment).
    3. Prepay outstanding Term B loans (if proceeds remain).

Material Changes and Agreements

The Company executed Amendment No. 4 to its Credit Agreement dated October 27, 2015. Key changes include:

  • Authorization for the sale of the AS&O product lines.
  • Mandated application of net cash proceeds from the sale to retire specific debt obligations.
  • Modification of the "Adjusted EBITDA" definition to allow adjustments for non-recurring expenses related to the AS&O sale.

Outlook, Contingencies, and Risks

Contingency: The redemption of the $360.0 million Senior Notes is strictly conditioned on the closing of the AS&O sale.
Timeline: The scheduled redemption date is July 10, 2018, subject to extension pending the closing of the AS&O sale.
Management Commentary: The filing indicates a strategic shift to reduce leverage and restructure debt obligations using proceeds from the divestiture of the AS&O lines.

Investor Verification Checklist

  • Confirm the closing status and final net cash proceeds of the AS&O product line sale.
  • Verify the exact redemption price calculation, including the applicable premium and accrued interest for the Senior Notes.
  • Monitor the July 10, 2018 redemption date for potential extensions if the AS&O sale is delayed.
  • Review the impact of the "Adjusted EBITDA" definition change on future covenant compliance.